Neo Ivy Capital Management Chemo Centryx, Inc. Transaction History

Neo Ivy Capital Management

$294 Million
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 16, 2022	SELL	$15.36 - $27.51 $95,416 - $170,892	-6,212 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$22.22 - $39.12 $85,480 - $150,494	3,847 Added 162.66%	6,212 $156,000
Q4 2021 Feb 15, 2022	BUY	$18.38 - $40.5 $43,468 - $95,782	2,365 New	2,365 $86,000
Q1 2021 Oct 07, 2021	SELL	$49.53 - $68.4 $165,430 - $228,456	-3,340 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$47.25 - $65.16 $154,649 - $213,268	3,273 Added 4885.07%	3,340 $207,000
Q3 2020 Nov 17, 2020	SELL	$46.35 - $61.69 $165,933 - $220,850	-3,580 Reduced 98.16%	67 $3,000
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $119,366 - $185,194	3,647 New	3,647 $147,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Neo Ivy Capital Management with notifications on news.